GMP Tiered Cell Banking of Non-enzymatically Isolated Dermal Progenitor Fibroblasts for Allogenic Regenerative Medicine

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_66D94F68D9E8
Type
Partie de livre
Sous-type
Chapitre: chapitre ou section
Collection
Publications
Institution
Titre
GMP Tiered Cell Banking of Non-enzymatically Isolated Dermal Progenitor Fibroblasts for Allogenic Regenerative Medicine
Titre du livre
Methods in Molecular Biology
Auteur⸱e⸱s
Laurent Alexis, Scaletta Corinne, Michetti Murielle, Hirt-Burri Nathalie, de Buys Roessingh Anthony S., Raffoul Wassim, Applegate Lee Ann
Editeur
Springer US
ISBN
9781071613269
9781071613276
ISSN
1064-3745
1940-6029
ISSN-L
1064-3745
Statut éditorial
Publié
Date de publication
2020
Peer-reviewed
Oui
Volume
2286
Pages
25-48
Langue
anglais
Résumé
Non-enzymatically isolated primary dermal progenitor fibroblasts derived from fetal organ donations are ideal cell types for allogenic musculoskeletal regenerative therapeutic applications. These cell types are differentiated, highly proliferative in standard in vitro culture conditions and extremely stable throughout their defined lifespans. Technical simplicity, robustness of bioprocessing and relatively small therapeutic dose requirements enable pragmatic and efficient production of clinical progenitor fibroblast lots under cGMP standards. Herein we describe optimized and standardized monolayer culture expansion protocols using dermal progenitor fibroblasts isolated under a Fetal Transplantation Program for the establishment of GMP tiered Master, Working and End of Production cryopreserved Cell Banks. Safety, stability and quality parameters are assessed through stringent testing of progeny biological materials, in view of clinical application to human patients suffering from diverse cutaneous chronic and acute affections. These methods and approaches, coupled to adequate cell source optimization, enable the obtention of a virtually limitless source of highly consistent and safe biological therapeutic material to be used for innovative regenerative medicine applications.
Pubmed
Web of science
Création de la notice
26/05/2020 8:17
Dernière modification de la notice
20/07/2024 7:06
Données d'usage